Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

MONTREAL and LAUSANNE, Switzerland, Jan. 08, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm , a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. Knight expects to take over commercial activities from Debiopharm’s current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.  
“I am excited to partner again with Debiopharm for Trelstar®” said Jonathan Ross Goodman, Chief Executive Officer of Knight. “Given our team’s successful history in launching and building Trelstar® in Canada and our focus on expanding Knight’s oncology portfolio, we are well positioned to re-launch Trelstar®.”“Given the Knight team’s previous great success with Trelstar®, we believe Knight is the right Canadian  partner” said Thierry Mauvernay, President & Delegate of the Board, Debiopharm.  “We’re excited for Knight to take on the commercialization, reenergizing Trelstar®. The product became a treatment of reference in prostate cancer in Canada under the leadership of the current Knight team when they were at Paladin. The product is among the leading prostate cancer treatment options, with a proven efficacy and safety profile.”About Trelstar® (triptorelin)About Knight Therapeutics Inc.  

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at or
Forward-Looking StatementAbout Debiopharm

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, they identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us  
Follow us @DebiopharmNews at

CBJ Newsmakers

Discovery Drills 34.7 Meters of 617 g/t Silver Equivalent, Including 3Kilgore Project Achieves >92% Gold Recoveries